PREPARING FOR MARKET ENTRY: THE ROLE OF MEDICAL AFFAIRS
Turning Clinical Evidence Into a Strategy for Market Readiness and Beyond
Preparing for market entry starts well before regulatory approval. As your clinical evidence begins to mature, it is time to start thinking about how that evidence will support launch and what needs to be in place before your product reaches the market.
Who are the KOLs you need to engage? Where and how should your data be presented and published? What scientific questions are you likely to receive? Where are the evidence gaps? And what additional evidence might you need after approval?
These activities take time. Building the Medical Affairs strategy early helps ensure you are ready for approval, launch, and what comes next.
BUILDING THE MEDICAL AFFAIRS STRATEGY
Start Before Approval
You do not want to wait for approval to begin building Medical Affairs. As your clinical evidence matures, you can begin understanding the scientific landscape, identifying evidence gaps, developing external expert relationships, and determining how your data will be communicated.
This is also the time for Medical Affairs to work closely with Clinical, Regulatory, and Marketing. Each brings a different perspective, and working together early helps align the evidence, scientific strategy, product positioning, and launch plans.
The goal is to be preparing for approval, not reacting to it.
Understand Your Evidence and Identify the Gaps
Start with a clear understanding of what your evidence supports and where gaps remain. Consider the strength of the data, patient populations, clinical outcomes, limitations, and how your findings fit within the existing scientific landscape.From there, you can begin defining publication priorities, scientific communications, KOL engagement, medical education, and additional evidence needs.You need to know what the evidence allows you to say today and what you may still need to demonstrate tomorrow.
Develop Your KOL Strategy
KOL development is more than creating a list of influential physicians. You need to identify the experts who are relevant to your disease state, technology, patient population, and clinical evidence, and begin building meaningful scientific relationships.
Those conversations can provide valuable insight into unmet needs, clinical practice, your existing evidence, and the questions that may emerge as you approach the market.
Starting these relationships early also helps inform your publication strategy, congress planning, medical education, and future evidence generation.
Plan Your Publications and Congresses
Once you have clinical data, you need a plan for where, when, and how it will be communicated.
Which congresses are important? When are abstract deadlines? Which data warrant a podium presentation, poster, or publication? What publications are needed, and in what sequence?
Planning early allows you to coordinate data availability, congress timelines, publications, and KOL engagement rather than treating each activity separately.
Prepare for Scientific Communication and Education
As approval approaches, you need to be ready to communicate the evidence clearly and consistently.
That means developing the scientific narrative, core medical materials, educational resources, and tools needed to support scientific exchange. It also means making sure Medical Affairs, field medical teams, and other customer facing functions understand the data, its limitations, and the questions clinicians are likely to ask.
When the product reaches the market, you want to be prepared for credible, evidence based scientific exchange from day one.
Plan for Evidence Generation Beyond Approval
Approval does not mean evidence generation is finished.
Once your product enters the market, KOL engagement, field insights, clinical experience, and changes in the treatment landscape will identify new questions and opportunities.
Your evidence generation plan may include investigator initiated studies, real world evidence, additional clinical studies, or research collaborations. These programs can help address unanswered questions, strengthen the evidence base, and potentially support future claims, indications, patient populations, or expanded use.
The evidence you generate after approval should be part of the strategy, not an afterthought.
BE READY BEFORE THE MARKET IS
Preparing for market entry is more than waiting for approval and planning a launch. You need the scientific relationships, publications, communications, education, and evidence strategy in place to support the product when it reaches the market.
Starting early also gives Medical Affairs, Clinical, Regulatory, and Marketing time to work together and align around the broader development and launch strategy.
The strongest Medical Affairs strategies begin before approval and continue to evolve well beyond launch.
Preparing for Market Entry?
CIMI can help you build and execute a Medical Affairs strategy that supports launch readiness, scientific engagement, and continued evidence generation.